Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HSK7653 Monotherapy in Type 2 Diabetes
NCT04556851Phase 3Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cofrogliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoint: HbA1c change from baseline at 24 weeks. Started Sep 2020; status: completed.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04556851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556851.